Updated:
In8bio
In8bio was founded to commercialize gamma-delta T cell technology, a class of immune cells that bridge innate and adaptive immunity. William Ho serves as CEO,...
In8bio
In8bio was founded to commercialize gamma-delta T cell technology, a class of immune cells that bridge innate and adaptive immunity. William Ho serves as CEO, leading the company's pipeline of investigational cell therapies. The firm's wealth origin is not publicly disclosed, as it is a public company. The firm's strategy centers on allogeneic cell therapy, using donor-derived gamma-delta T cells engineered to target tumors. It has two lead investigational products: INB-200 for glioblastoma and INB-100 for hematologic malignancies. In8bio also develops a platform to enhance cell persistence and tumor trafficking. The geographic footprint is US-based, with clinical trial sites primarily in North America. As a public company, In8bio reports no standard AUM. It had approximately 58 employees as of its latest filings. The firm operates from its New York City headquarters. In December 2023, In8bio presented updated clinical data for INB-100 at the American Society of Hematology annual meeting (per public release, December 2023). In8bio's structural differentiator lies in its exclusive focus on gamma-delta T cells, a less crowded area of cell therapy compared to CAR-T. This niche approach allows the firm to target solid tumors and hematologic cancers with a potential off-the-shelf product, reducing manufacturing complexity.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Principals
William Ho
CEO and Director
Sector focus
Frequently asked questions
What is the core technology platform at In8bio?
In8bio focuses on gamma-delta T cells, a type of immune cell that can target tumors without requiring HLA matching. The firm develops both autologous and allogeneic therapies using this platform, aiming for off-the-shelf cell therapy products.
Which clinical trials is In8bio currently running?
In8bio has two lead programs: INB-200 for newly diagnosed glioblastoma multiforme and INB-100 for patients with hematologic malignancies undergoing stem cell transplant. Both are in Phase 1 clinical trials in the United States.
How does In8bio differentiate from CAR-T companies?
Unlike CAR-T therapies that rely on engineered T cells targeting a single antigen, In8bio's gamma-delta T cells can target multiple tumor antigens through natural killer-like mechanisms, potentially reducing relapse risk and enabling therapy for solid tumors.
Is In8bio a single family office or a public company?
In8bio is a publicly traded biotechnology company listed on the Nasdaq under the ticker INAB. It operates as a clinical-stage therapeutic development firm, not a family office or investment vehicle.
What is the investment stage for In8bio?
In8bio is a clinical-stage company, meaning its therapies are in human trials but not yet commercialized. It generates no product revenue and relies on equity financing, grants, and partnerships to fund operations.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: